AC-0682
- Generic Name
- AC-0682
A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Accutar Biotechnology Inc
- Target Recruit Count
- 6
- Registration Number
- NCT05489679
- Locations
- 🇨🇳
Site 1003, Hangzhou, China
🇨🇳Site 1001, Beijing, China
🇨🇳Site 1002, Tianjin, China
A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Accutar Biotechnology Inc
- Target Recruit Count
- 21
- Registration Number
- NCT05080842
- Locations
- 🇺🇸
Site 03, Nashville, Tennessee, United States
🇺🇸Site 02, Sarasota, Florida, United States
🇺🇸Site 01, Denver, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath